

Table S1. In vitro inhibition of all target compounds for LO2 normal cells.

Compound	Inhibition rate (% of control)	
	10 μ M	5 μ M
6a	4.47 $\pm$ 1.20	3.53 $\pm$ 1.22
6b	4.37 $\pm$ 0.65	3.56 $\pm$ 1.42
6c	8.89 $\pm$ 2.83	8.27 $\pm$ 1.60
6d	9.34 $\pm$ 1.27	4.13 $\pm$ 0.17
6e	9.17 $\pm$ 3.69	6.29 $\pm$ 0.63
6f	17.92 $\pm$ 2.53	5.88 $\pm$ 6.76
6g	6.16 $\pm$ 1.20	6.11 $\pm$ 2.58
6h	6.56 $\pm$ 0.60	6.25 $\pm$ 2.64
10a	25.57 $\pm$ 1.23	11.98 $\pm$ 0.34
10b	28.56 $\pm$ 0.91	23.27 $\pm$ 2.23
10c	23.07 $\pm$ 3.93	20.51 $\pm$ 2.09
13a	12.45 $\pm$ 0.24	9.37 $\pm$ 2.13
13b	11.37 $\pm$ 2.56	8.86 $\pm$ 1.38
13c	11.85 $\pm$ 3.17	5.29 $\pm$ 1.37
Cisplatin	32.19 $\pm$ 1.90	26.57 $\pm$ 4.51

Table S2. In vitro inhibition of target compounds combined with cisplatin for LO2 normal cells.

	Inhibition rate (% of control)		
	Cisplatin (2.5 μ M)	Target compound (2.5 μ M)	Cisplatin (2.5 μ M) + Target compound (2.5 μ M)
	12.12 $\pm$ 0.36		
6a		2.26 $\pm$ 1.46	3.73 $\pm$ 0.39
6b		3.14 $\pm$ 0.68	4.07 $\pm$ 1.35
6c		4.98 $\pm$ 2.39	4.54 $\pm$ 1.21
6d		4.39 $\pm$ 1.46	6.26 $\pm$ 2.14
6e		5.98 $\pm$ 3.19	4.23 $\pm$ 9.37
6f		2.10 $\pm$ 0.83	7.26 $\pm$ 1.50
6g		3.23 $\pm$ 1.38	4.58 $\pm$ 2.40
6h		2.98 $\pm$ 0.70	0.99 $\pm$ 0.10
10a		10.63 $\pm$ 1.91	9.89 $\pm$ 2.17
10b		17.83 $\pm$ 3.73	10.04 $\pm$ 2.97
10c		21.22 $\pm$ 2.99	5.27 $\pm$ 8.03
13a		8.64 $\pm$ 1.13	7.29 $\pm$ 2.06
13b		8.19 $\pm$ 0.37	8.26 $\pm$ 1.12
13c		4.38 $\pm$ 0.56	3.75 $\pm$ 1.23